ストックスクリーナーアプリを入手
1.32
5.60%
0.07
プレマーケット:
1.32
Immunic Inc (IMUX) 最新ニュース
IMUX SEC FilingsImmunic Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Guggenheim initiates coverage of Immunic (IMUX) with buy recommendation - MSN
If You Invested $1,000 in Immunic Inc (IMUX) - Stock Titan
Immunic stock jumps after Guggenheim initiates with Buy By Investing.com - Investing.com Canada
Immunic (IMUX) Gains on Guggenheim's Buy Rating and Promising Drug Potential - GuruFocus
Immunic stock jumps after Guggenheim initiates with Buy - Investing.com UK
Immunic stock gains new Buy at Guggenheim (IMUX:NASDAQ) - Seeking Alpha
Immunic (NASDAQ:IMUX) Earns Buy Rating from Analysts at Guggenheim - MarketBeat
IMUX: Guggenheim Initiates Coverage with a Buy Rating and $7 Pri - GuruFocus
Immunic stock initiated at Buy by Guggenheim on MS therapy potential By Investing.com - Investing.com South Africa
Immunic stock initiated at Buy by Guggenheim on MS therapy potential - Investing.com
Immunic, Inc. (NASDAQ:IMUX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Tangible book value per share of Immunic, Inc. – FWB:10VA - TradingView
Bull Bear: Does Immunic Inc meet Warren Buffetts criteria2026 Sector Moves & Expert-Curated Trade Recommendations - baoquankhu1.vn
US Stocks Recap: Will Immunic Inc stock recover after earningsFed Meeting & Weekly Return Optimization Alerts - baoquankhu1.vn
Immunic, Inc. (IMUX) announces European patent grant for vidofludimus calcium - MSN
Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus Calcium - Insider Monkey
Immunic Conference: “Transformative” 2026 Ahead With Pivotal MS Data Due Late Year, NDA Next - MarketBeat
Immunic at Stifel CNS Forum: Strategic Insights on MS Drug By Investing.com - Investing.com Canada
Immunic at Stifel CNS Forum: Strategic Insights on MS Drug - Investing.com
Immunic Details Vidofludimus Calcium MS Strategy, Phase III Timeline at Leerink Conference - MarketBeat
Immunic Inc Stock Operating Data - GuruFocus
Why did IMUX stock surge 33% pre-market today? - MSN
Short Interest in Immunic, Inc. (NASDAQ:IMUX) Rises By 14.5% - MarketBeat
Immunic Stock Under Pressure Amid Financial Changes and Market Reactions - StocksToTrade
Immunic Shares Rise Amid Resilient Strategy In Uncertain Markets - timothysykes.com
Immunic Inc. Faces Slow Recovery Amid Financial Struggles - StocksToTrade
symbol__ Stock Quote Price and Forecast - CNN
Should Extended European Patent Protection for Vidofludimus Calcium Reshape Immunic’s (IMUX) Long-Term Value Proposition? - simplywall.st
New European patent covers all dosing regimens of experimental MS therapy - Multiple Sclerosis News Today
A Look At Immunic (IMUX) Valuation As Reverse Split Proposal And Conference Appearance Draw Attention - simplywall.st
Volume Recap: What makes Immunic Inc stock attractive today2026 Closing Moves & Consistent Return Investment Signals - baoquankhu1.vn
Immunic at Leerink Global Healthcare Conference: Strategic Insights on MS Drug - Investing.com Australia
Immunic at Leerink Global Healthcare Conference: Strategic Insights on MS Drug By Investing.com - Investing.com India
Immunic secures European patent for vidofludimus calcium dosing By Investing.com - Investing.com Canada
Small cap wrap: Immunic, AtaiBeckley, Standard Uranium, Trust Stamp… - Proactive Investors
Immunic secures European patent for vidofludimus calcium dosing - Investing.com Nigeria
Immunic (IMUX) Secures Key European Patent for Vidofludimus Calc - GuruFocus
Biopharmaceutical company Immunic, Inc. announced that it has been granted a key European patent, which will provide important protection for the administration regimen related to Vidofludimus calcium. - Bitget
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium - PR Newswire
Immunic secures European patent for MS drug candidate vidofludimus calcium - Proactive financial news
What makes Immunic Inc. (10VA) stock appealing to growth investorsOil Prices & Real-Time Volume Surge Alerts - Naître et grandir
IMUX Forecast, Price Target & Analyst Ratings | IMMUNIC INC (NASDAQ:IMUX) - ChartMill
IMUX Earnings History & Surprises | EPS & Revenue Results | IMMUNIC INC (NASDAQ:IMUX) - ChartMill
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - Stocktwits
Earnings Update: Whats the analyst consensus on Immunic IncDay Trade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
HC Wainwright Has Bearish Estimate for Immunic Q1 Earnings - MarketBeat
Deep Track group reports 11.45M-share stake in Immunic (IMUX) - Stock Titan
1.82%
大文字化:
|
ボリューム (24 時間):